Editas Medicine, Inc.
A biotech company that develops treatments for serious diseases by editing genes with CRISPR, a molecular tool that snips and rewrites DNA. Founded in 2013 in Cambridge, Massachusetts, it was started by pioneers of the field including Jennifer Doudna and Feng Zhang, and its name comes from the Latin word "edit." Its medicines aim at inherited conditions such as blood disorders and cardiovascular disease.
Granted 411.8K · Sold 163.5K
Granted 166.2K · Sold 32.8K
Granted 139.2K · Sold 26.4K
Granted 89.5K · Sold 11.6K
Granted 73.0K · Sold 32.1K
Granted 57.8K · Sold 11.0K
Bought 45.0K
Granted 85.0K · Sold 23.5K
Granted 40.8K · Sold 7.9K
Granted 4.2K · Sold 1.6K
Sold 3.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| O'Neill Gilmore NeilCEO, Director · 16 transactions | — | 248.3K | 411.8K | — | 163.5K |
| Mei BaisongEVP, CHIEF MEDICAL OFFICER · 11 transactions | — | 133.4Kas of Dec 2024 | 166.2K | — | 32.8K |
| Lucera ErickEVP, CHIEF FINANCIAL OFFICER · 5 transactions | — | 112.7Kas of Mar 2025 | 139.2K | — | 26.4K |
| Robertson MichelleEVP, CHIEF FINANCIAL OFFICER · 12 transactions | +271% | 106.6Kas of May 2023 | 89.5K | — | 11.6K |
| Mullen James CCEO, Director · 4 transactions | +116.9% | 75.9Kas of Jan 2022 | 73.0K | — | 32.1K |
| Eaton BruceEVP, CBO AND CTO · 25 transactions | +9.8% | 74.8Kas of Dec 2023 | 57.8K | — | 11.0K |
| Hopfield JessicaDirector · 1 transaction | +198.2% | 67.7Kas of May 2024 | — | 45.0K | — |
| Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER · 11 transactions | — | 67.3K | 85.0K | — | 23.5K |
| Shearman Mark SEVP, CHIEF SCIENTIFIC OFFICER · 4 transactions | — | 65.6Kas of Feb 2023 | 40.8K | — | 7.9K |
| Michaels Lisa AnneEVP/Chief Medical Officer · 2 transactions | — | 22.7Kas of Dec 2021 | 4.2K | — | 1.6K |
| Parison AmySVP, Chief Financial Officer · 6 transactions | — | 15.0K | — | — | 3.0K |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 5 years: -268.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.